Insider · CIK 0001655962
Charles N York II
cfocooofficer
Files at DAWN (Day One Biopharmaceuticals, Inc.). First filing Nov 19, 2024, latest Feb 18, 2026.
Charles N York II files SEC Form 4 as CFO and COO at DAWN (Day One Biopharmaceuticals, Inc.). Since Nov 19, 2024, Charles N York II has reported 0 open-market buys worth $0 and 6 open-market sells worth $248k, the latest filed on Feb 18, 2026.
A track record needs three past buys with six months of prices behind them; Charles N York II has 0, so none is measured yet.
The newest scored trade: sold $70k of DAWN on Feb 17, 2026, filed Feb 18, 2026, scored 30 (weak). In the last 12 months: 0 buys worth $0 and 2 sells worth $107k.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 6
$0 bought, $248k sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Day One Biopharmaceuticals, Inc. | $70k 6,065 shares | -2% | - | |
| 28Weak | Day One Biopharmaceuticals, Inc. | $36k 4,062 shares | -1% | - | |
| 27Weak | Day One Biopharmaceuticals, Inc. | $28k 4,106 shares | -1% | - | |
| 27Weak | Day One Biopharmaceuticals, Inc. | $27k 4,282 shares | -2% | - | |
| 29Weak | Day One Biopharmaceuticals, Inc. | $52k 4,370 shares | -2% | - | |
| 28Weak | Day One Biopharmaceuticals, Inc. | $34k 2,602 shares | -1% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 17, 2025 | DAWN DAY ONE BIOPHARMACEUTICALS, INC. | 4,062 0.00% of outstanding | $36k | Nov 17, 2025 | $28k |
| May 16, 2025 | DAWN DAY ONE BIOPHARMACEUTICALS, INC. | 4,282 0.00% of outstanding | $27k | May 16, 2025 | $52k |
| Feb 18, 2025 | DAWN DAY ONE BIOPHARMACEUTICALS, INC. | 4,370 0.00% of outstanding | $52k | Feb 18, 2025 | none |
Transactions
The newest 50 of 77 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Common Stock | -312,025 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -497,667 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -151,000 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -116,000 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -162,000 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -162,000 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -188,000 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Restricted Stock Unit (RSU)derivative | -6,750 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Restricted Stock Unit (RSU)derivative | -46,375 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Restricted Stock Unit (RSU)derivative | -72,875 | - | - | 0 | Apr 23, 2026 |
| Apr 23, 2026 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Restricted Stock Unit (RSU)derivative | -118,125 | - | - | 0 | Apr 23, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +2,250 | - | - | 296,965 | Feb 18, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +6,625 | - | - | 303,590 | Feb 18, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +6,625 | - | - | 310,215 | Feb 18, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +7,875 | - | - | 318,090 | Feb 18, 2026 |
| Feb 17, 2026 | DAWN Day One Biopharmaceuticals, Inc. | SOpen-market sale Common Stock | -6,065 | $11.60 | $70k | 312,025 | Feb 18, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -2,250 | $0.00 | $0 | 6,750 | Feb 18, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 46,375 | Feb 18, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 72,875 | Feb 18, 2026 |
| Feb 15, 2026 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -7,875 | $0.00 | $0 | 118,125 | Feb 18, 2026 |
| Jan 30, 2026 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +188,000 | $0.00 | $0 | 188,000 | Jan 30, 2026 |
| Jan 30, 2026 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Restricted Stock Unitsderivative | +126,000 | $0.00 | $0 | 126,000 | Jan 30, 2026 |
| Nov 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +1,375 | - | - | 283,277 | Nov 18, 2025 |
| Nov 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +2,250 | - | - | 285,527 | Nov 18, 2025 |
| Nov 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +6,625 | - | - | 292,152 | Nov 18, 2025 |
| Nov 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +6,625 | - | - | 298,777 | Nov 18, 2025 |
| Nov 17, 2025 | DAWN Day One Biopharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,062 | $8.91 | $36k | 294,715 | Nov 18, 2025 |
| Nov 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -1,375 | $0.00 | $0 | 0 | Nov 18, 2025 |
| Nov 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -2,250 | $0.00 | $0 | 9,000 | Nov 18, 2025 |
| Nov 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 53,000 | Nov 18, 2025 |
| Nov 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 79,500 | Nov 18, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -497,667 | $0.00 | $0 | 0 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +497,667 | $0.00 | $0 | 497,667 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -151,000 | $0.00 | $0 | 0 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +151,000 | $0.00 | $0 | 151,000 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -116,000 | $0.00 | $0 | 0 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +116,000 | $0.00 | $0 | 116,000 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -162,000 | $0.00 | $0 | 0 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +162,000 | $0.00 | $0 | 162,000 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | DDisposition to issuer Stock Option (right to buy Common Stock)derivative | -162,000 | $0.00 | $0 | 0 | Nov 7, 2025 |
| Nov 6, 2025 | DAWN Day One Biopharmaceuticals, Inc. | AGrant or award Stock Option (right to buy Common Stock)derivative | +162,000 | $0.00 | $0 | 162,000 | Nov 7, 2025 |
| Aug 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +1,375 | - | - | 266,606 | Aug 19, 2025 |
| Aug 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +2,250 | - | - | 268,856 | Aug 19, 2025 |
| Aug 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +6,625 | - | - | 275,481 | Aug 19, 2025 |
| Aug 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Common Stock | +6,625 | - | - | 282,106 | Aug 19, 2025 |
| Aug 18, 2025 | DAWN Day One Biopharmaceuticals, Inc. | SOpen-market sale Common Stock | -4,106 | $6.77 | $28k | 278,000 | Aug 19, 2025 |
| Aug 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -1,375 | $0.00 | $0 | 1,375 | Aug 19, 2025 |
| Aug 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -2,250 | $0.00 | $0 | 11,250 | Aug 19, 2025 |
| Aug 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 59,625 | Aug 19, 2025 |
| Aug 15, 2025 | DAWN Day One Biopharmaceuticals, Inc. | MOption exercise Restricted Stock Unit (RSU)derivative | -6,625 | $0.00 | $0 | 86,125 | Aug 19, 2025 |
50 of 77 rows shown.
Questions about Charles N York II
Answered from the filings on this page, as of the latest one.
Is Charles N York II buying or selling?
In the last 12 months Charles N York II reported 0 open-market buys worth $0 and 2 open-market sells worth $107k on SEC Form 4; the latest was sold $70k of DAWN on Feb 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Charles N York II's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Charles N York II has 0.
Where does Charles N York II file Form 4?
Charles N York II has filed Form 4 at DAWN (Day One Biopharmaceuticals, Inc.) as COO and CFO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.